Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase 4 Study to Evaluate the Efficacy and Safety of Entyvio (Vedolizumab IV) in the Treatment of Chronic Pouchitis (EARNEST)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vedolizumab (Primary) ; Ciprofloxacin
Indications Pouchitis
Focus Therapeutic Use
Acronyms EARNEST
Sponsors Takeda

Most Recent Events

09 May 2023 Results presented at the Digestive Disease Week 2023
30 Mar 2023 According to a Takeda media release, Canadian investigators played an important role in the development and execution of this study.
30 Mar 2023 According to a Takeda media release, results from this trial were published in New England Journal of Medicine.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com